Display options
Share it on

Postepy Dermatol Alergol. 2014 Oct;31(5):294-8. doi: 10.5114/pdia.2014.44019. Epub 2014 Oct 22.

Triggering drug use in patients with psoriasis: an investigative report from Turkey.

Postepy dermatologii i alergologii

Zerrin Ogretmen, Ulku Askin, Meliha Merve Hiz, Sibel Cevizci

Affiliations

  1. Department of Dermatology, School of Medicine, Çanakkale Onsekiz Mart University, Canakkale, Turkey. Head of Department: Prof. Zerrin Ö?retmen MD.
  2. Department of Dermatology, Baskent University Zübeyde Han?m Training and Research Center, Izmir, Turkey. Head of Department: Prof. Tülin Güleç MD.
  3. Department of Biology, The Faculty of Arts and Sciences, Canakkale Onsekiz Mart University, Canakkale, Turkey. Head of Department: Prof. ?smet Uysal PhD.
  4. Department of Public Health, School of Medicine, Canakkale Onsekiz Mart University, Canakkale, Turkey. Head of Department: Assoc. Prof. Ço?kun Bakar MD.

PMID: 25395925 PMCID: PMC4221355 DOI: 10.5114/pdia.2014.44019

Abstract

INTRODUCTION: The patients clinically diagnosed with psoriasis were investigated for drug use that may trigger psoriasis.

AIM: To minimize the triggering drug use and help the medical treatment of psoriasis patients.

MATERIAL AND METHODS: The study involved 289 psoriatic patients who attended our clinic in 2010-2012 and were asked to bring their drug lists of the last year, which they obtained from the pharmacy's record system. They were advised not to use the drugs that may trigger psoriasis. Data analyses were performed using SPSS program version 19.0.

RESULTS: A total of 289 patients were included in the study. Two hundred and twenty-one patients were using non-steroidal anti-inflammatory drugs; 133 patients were using anti-reflux drugs; 35 patients were using antidiabetic drugs; 31 patients were using calcium-channel blockers and 24 patients were using β-blockers. In our study group, there was no significantly difference between median PASI scores of the patients using a triggering drug and those of who are not using a triggering drug. However, there was a positive low correlation between PASI rates and numbers of drugs used (r = 0.180, p = 0.013).

CONCLUSIONS: Many other factors may trigger psoriasis, therefore the effect of stopping or minimizing the drug use on disease remission is not known. Because of the high triggering drug use rate, it is important to enlighten psoriasis patients about triggering drugs.

Keywords: non-steroidal anti-inflammatory drugs; psoriasis; triggering drugs; β-blockers

References

  1. Diabetologia. 2011 Nov;54(11):2745-54 - PubMed
  2. Eur J Dermatol. 1998 Dec;8(8):563-8 - PubMed
  3. Clin Exp Rheumatol. 2010 May-Jun;28(3):408-10 - PubMed
  4. Am J Ther. 2011 May;18(3):e78-80 - PubMed
  5. J Am Acad Dermatol. 1988 Oct;19(4):629-32 - PubMed
  6. Tijdschr Psychiatr. 2012;54(3):285-9 - PubMed
  7. Arch Dermatol. 1988 Jun;124(6):854-5 - PubMed
  8. Acta Derm Venereol. 2001 Oct-Nov;81(5):347-9 - PubMed
  9. Skin Therapy Lett. 2011 Apr;16(4):5-6 - PubMed
  10. Acta Dermatovenerol Croat. 2003;11(1):17-21 - PubMed
  11. J Clin Pharm Ther. 2008 Jun;33(3):321-5 - PubMed
  12. J Dermatolog Treat. 2009;20(2):100-8 - PubMed
  13. Ugeskr Laeger. 1991 Jan 7;153(2):132 - PubMed
  14. J Clin Psychopharmacol. 2009 Apr;29(2):134-40 - PubMed
  15. Ann Dermatol Venereol. 2000 Mar;127(3):279-81 - PubMed
  16. Gen Hosp Psychiatry. 2010 Jul-Aug;32(4):446.e9-446.e10 - PubMed
  17. Cutis. 1979 Jul;24(1):95-8 - PubMed
  18. J Dermatol. 1993 May;20(5):279-86 - PubMed
  19. J Am Acad Dermatol. 1997 Jun;36(6 Pt 1):932-4 - PubMed
  20. J Am Acad Dermatol. 1987 Nov;17(5 Pt 2):918-20 - PubMed
  21. CMAJ. 2009 Jul 7;181(1-2):60 - PubMed
  22. Am J Clin Dermatol. 2000 May-Jun;1(3):159-65 - PubMed
  23. J Clin Aesthet Dermatol. 2010 Jan;3(1):32-8 - PubMed
  24. Dermatol Online J. 2003 Aug;9(3):11 - PubMed
  25. Harefuah. 1994 Oct;127(7-8):228-9, 287 - PubMed
  26. Int J Dermatol. 2010 Dec;49(12):1351-61 - PubMed
  27. Dermatologica. 1982 Sep;165(3):197-203 - PubMed
  28. Ugeskr Laeger. 1997 Jan 27;159(5):598-600 - PubMed
  29. Clin Rheumatol. 1991 Jun;10(2):178-80 - PubMed
  30. Semin Dermatol. 1992 Dec;11(4):269-74 - PubMed
  31. Acta Derm Venereol. 1984;64(4):346-8 - PubMed
  32. J Hepatol. 2010 Sep;53(3):587 - PubMed
  33. Br J Dermatol. 2004 May;150(5):966-9 - PubMed
  34. J Rheumatol Suppl. 2009 Aug;83:59-61 - PubMed
  35. Actas Esp Psiquiatr. 2002 Nov-Dec;30(6):400-3 - PubMed
  36. Prim Care Companion J Clin Psychiatry. 2008;10(6):435-9 - PubMed
  37. Cutis. 1986 Jul;38(1):45 - PubMed
  38. J Am Acad Dermatol. 1994 Jun;30(6):1045 - PubMed
  39. J Drugs Dermatol. 2006 May;5(5):426-32 - PubMed
  40. Gastroenterol Hepatol. 2011 Oct;34(8):546-50 - PubMed
  41. J Am Acad Dermatol. 1997 May;36(5 Pt 2):858-62 - PubMed
  42. Australas J Dermatol. 2012 Feb;53(1):70-2 - PubMed
  43. N Z Med J. 1993 Sep 8;106(963):392-3 - PubMed
  44. Eur J Dermatol. 2003 Jul-Aug;13(4):404-5 - PubMed
  45. J Am Acad Dermatol. 1986 Nov;15(5 Pt 1):1007-22 - PubMed
  46. Clin Dermatol. 2007 Nov-Dec;25(6):606-15 - PubMed
  47. Adv Exp Med Biol. 1999;455:221-5 - PubMed
  48. Ann Pharmacother. 1992 Feb;26(2):211-2 - PubMed

Publication Types